Edge Medical Ventures is a medtech-focused venture studio and fund managed by industry veterans with extensive operational experience.
Our mission is to create or identify ventures that offer significant market opportunities by addressing critical clinical unmet needs through the development and investment in breakthrough medical device technologies.
Our venture studio, EdgeLabs, is designed to start from a unmet need posed by our strategic collaborators. Our later-stage fund, EdgeMED, typically invests in seed, Series A, and early Series B rounds (up to $3M)—primarily at the clinical stage.
A key goal of Edge is to act as a bridge between Israeli innovation and the U.S. market, by actively supporting our portfolio companies in making this transition. This includes guidance in clinical operations, preparation for commercial launch, networking with leading U.S. healthcare systems, and establishing U.S.-based offices and personnel. We achieve this through our strong collaborations with strategic players, healthcare systems, and investors across the United States.
Venture Creation Studio based on validated unmet market needs
Venture Capital Fund focused on investing in medical device companies
Built on Experience. Driven by Vision.
Edge Medical Ventures was founded by the leadership team of MEDX Xelerator—Israel’s leading medical device incubator. Since 2018, MEDX has launched and invested in 18 medical device companies, shaping a new generation of healthcare innovation.
To continue supporting these companies beyond their incubation phase—and to back the next wave of transformative technologies—we founded Edge.
Edge Medical Ventures is the natural evolution of our journey: a fund built on deep operational experience, clinical insight, and a track record of value creation in early-stage Medtech.
Through Edge, we extend the lifecycle of support that began at MEDX—investing in bold ideas and scaling breakthrough solutions to global impact.
Learn more about MEDX Xelerator
If you have a big , back it heavily because you don’t get a big
often. Opportunity comes, but it doesn’t come often, so seize it when it does come
Charlie Munger

January 20, 2026
Event convenes startups, investors, and local representatives, highlights Edge - NJ Economic Development Authority (NJEDA) partnership in attracting medtech innovation to the state

January 12, 2026
$1 Million NJIEF Investment Matches Edge Medical Ventures Funding to Expand US Commercialization

December 10, 2025
Partnership leverages proven ARC innovation model and Edge venture studio expertise to build indusrty startups through public-private collaboration

October 8, 2025
Clinically proven airway clearance solution now available; Company to showcase device at CHEST 2025 and NACFC 2025

September 16, 2025
Enrollment milestone advances Exero Medical toward planned FDA submission of its breakthrough designated xBar system for early anastomotic leak detection.

September 16, 2025
Designation supports accelerated development of AI-driven platform to improve outcomes and reduce clinical burden.

July 10, 2025
With Planned Market Expansion Following FDA Milestone, Company Establishes U.S. Headquarters in Jersey City

April 10, 2025
We're honored and proud to share that Edge Medical Ventures has won the Israel Innovation Authority tender for the next Technological Incubator Program.

February 20, 2025
PatenSee has secured a $2M first close of a seed round to advance clinical activities toward FDA approval.

February 13, 2025
Exero Medical has secured up to $12.7M in funding to complete its FDA pivotal trial and launch its breakthrough-designated xBar system in the United States.

September 12, 2024
Edge Medical Ventures, a venture firm that grew out of Israeli medical-technology incubator MEDX Xelerator, has raised $15 million toward a $70 million debut fund